Screener
Nurix Therapeutics, Inc. NRIX Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $9.04M-79.5% | $6.25M-66.1% | $13.58M+2.2% | $7.89M-37.3% | $44.06M+264% | ||
| $87.65M+12.2% | $84.14M+20.8% | $83.02M+23.5% | $86.12M+55.2% | $78.1M+59.6% | ||
| $15.59M+9.2% | $14.61M+25.4% | $13.65M+27.3% | $13.16M+12.3% | $14.28M+22.0% | ||
| $103.25M+11.8% | $98.75M+21.4% | $96.67M+24.0% | $99.28M+47.7% | $92.38M+52.4% | ||
| -$94.2M-95.0% | -$92.5M-47.1% | -$83.1M-28.5% | -$91.39M-67.3% | -$48.32M+0.4% | ||
| -1,041.7%-932pp | -1,479.4%-1,139pp | -612%-125pp | -1,157.7%-724pp | -109.7%+292pp | ||
| -$89.81M-110% | —— | -$78.22M-33.6% | -$86.42M-76.8% | -$42.7M+3.9% | ||
| -$271K-136% | —— | $0-100% | $0-100% | $760K+744% | ||
| -$89.54M-106% | -$87.17M-54.7% | -$78.22M-33.6% | -$86.42M-76.5% | -$43.46M+2.4% | ||
| -990.1%-891pp | -1,394.3%-1,089pp | -576.1%-135pp | -1,094.8%-706pp | -98.7%+270pp | ||
| -$0.81-55.8% | -$0.79-17.9% | -$0.83-10.7% | -$1.03-53.7% | -$0.52+26.8% | ||
| -$91.95M-99.5% | -$90.3M-49.2% | -$80.98M-30.4% | -$89.36M-71.1% | -$46.08M+0.3% | ||
| -1,016.8%-912pp | -1,444.3%-1,116pp | -596.4%-129pp | -1,132%-717pp | -104.6%+278pp | ||
| -$94.2M-95.0% | -$92.5M-47.1% | -$83.1M-28.5% | -$91.39M-67.3% | -$48.32M+0.4% |
FAQ
- What is Nurix Therapeutics, Inc.'s revenue?
- Nurix Therapeutics, Inc. (NRIX) generated $36.8M in revenue over the trailing twelve months, down 58.4% year over year.
- Is Nurix Therapeutics, Inc. profitable?
- Nurix Therapeutics, Inc. is not currently profitable: it reported a net loss of $341.4M over the trailing twelve months, a -928.4% net margin.
- What is Nurix Therapeutics, Inc.'s earnings per share?
- Nurix Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-3.46.
- Where does Nurix Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Nurix Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
